National Association of Pharmacy Regulatory Authorities
National Association of Pharmacy Regulatory Authorities

Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Reset
Print Friendly
Drug Name Comment Schedule Date
Benztropine or its salts

including but not limited to benzatropine

 I DEC / 13
Benzydamine or its salts I DEC / 13
Benzyl benzoate II SEP / 98
Bepotastine or its salts or derivatives I NOV / 16
Beractant I DEC / 13
Besifloxacin or its salts I DEC / 13
Betahistine or its salts I DEC / 13
Betaine or its salts

for human use, when sold or recommended for the treatment of homocystinuria

 I DEC / 13
Betaine or its salts.

for veterinary use

 I DEC / 13
Betaxolol or its salts I DEC / 13
Bethanechol chloride I DEC / 13
Bethanidine or its salts I DEC / 13
Bevacizumab I DEC / 13
Bezafibrate or its salts or derivatives I DEC / 13
Bicalutamide I DEC / 13
Bictegravir or its salts I AUG / 18
Bilastine or its salts or derivatives I AUG / 16
Biperiden or its salts I DEC / 13
Bisacodyl when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50mg of bisacodyl U JAN / 14
Bisacodyl and its salts

(except when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl)

 III JAN / 14
Bishydroxycoumarin or its salts or derivatives I DEC / 13
Bisoprolol or its salts I DEC / 13
Bitolterol or its salts I DEC / 13
Bivalirudin I DEC / 13
Bleomycin I DEC / 13
Blinatumomab I AUG / 16
Boceprevir or its derivatives I DEC / 13
Boric acid and its salts in preparations for systemic use, or ophthalmic preparations in concentrations over 2%[Note: does not apply to contact lens solutions intended to be rinsed off prior to insertion in the eye] II DEC / 98
Bortezomib I DEC / 13
Bosentan or its salts or derivatives I DEC / 13
Bosutinib or its salts

including but not limited to Bosutinib methanoate

 I AUG / 14
Botulinum toxin

including but not limited to onabotulinumtoxin A, incobotulinumtoxin A, abobotulinumtoxin A, rimabotulinumtoxin B, prabotulinumtoxin A

 I DEC / 13
Brentuximab vedotin I DEC / 13
Bretylium tosylate I DEC / 13
Brexpiprazole or its salts I APR / 17
Brigatinib or its salts I AUG / 18
Brimonidine or its salts I DEC / 13
Brivaracetam or its derivatives I AUG / 16
Brodalumab I MAY / 18
Brolucizumab I JUL / 20
Bromal I DEC / 13
Bromal hydrate I DEC / 13
Brometone I DEC / 13
Bromfenac or its salts I MAY / 15
Bromisoval I DEC / 13
Bromocriptine or its salts I DEC / 13
Bromoform I DEC / 13
Brompheniramine and its salts as a single entity for the treatment of allergies III JAN / 03
Brompheniramine and its salts. in combination products for the relief of cough and cold symptoms U JAN / 03
Buclizine II SEP / 98
Bufexamac II SEP / 98
Bumetanide or its salts or derivatives I DEC / 13
Bupivacaine and its salts for topical use on mucous membranes except lozenges III SEP / 98
Bupivacaine and its salts for parenteral or ophthalmic use II SEP / 98
Bupropion or its salts I DEC / 13
Burosumab I DEC / 18
Buserelin or its salts I DEC / 13
Buspirone or its salts I DEC / 13
Busulfan I DEC / 13
Butacaine and its salts for ophthalmic or parenteral use II SEP / 98
Butaperazine or its salts I DEC / 13
Butenafine 1% cream U SEP / 99
Butoconazole or its salts I DEC / 13
Butorphanol and its salts C I JUN / 02
Butyl chloral hydrate I DEC / 13
Cabergoline or its salts I DEC / 13
Cabotegravir or its salts I JUL / 20
Cabozantinib or its salts I NOV / 18
Calcifediol I JUL / 18
Calcipotriol I DEC / 13
Calcitonin I DEC / 13
Calcitriol I DEC / 13
Calcium bromide I DEC / 13
Calcium bromolactobionate I DEC / 13
Calcium carbimide I DEC / 13
Calcium chloride in injectable form for parenteral nutrition I JAN / 03
Calcium disodium edetate II SEP / 98
Calcium gluconate in injectable form for parenteral nutrition I JAN / 03
Calcium polycarbophil III SEP / 98
Calcium salts when sold for the treatment of hyperphosphatemia I DEC / 13
Camphor in oleaginous vehicles and in liquid forms in concentrations greater than 11% II OCT / 98
Canagliflozin I JUL / 14
Canakinumab I DEC / 13
Candesartan or its salts or derivatives

including but not limited to candesartan cilexetil

 I DEC / 13
Candicidin or its salts or derivatives I DEC / 13
Cantharides, their preparations and derivatives II SEP / 98
Caplacizumab I JUL / 20
Capreomycin or its salts ir deriviatives I DEC / 13
Captodiamine or its salts I DEC / 13
Captopril or its salts I DEC / 13
Carbachol I DEC / 13
Carbamazepine I DEC / 13
Carbapenem salts or derivatives

Including but not limited to: Doripenem, ertapenem, imipenem, meropenem

 I DEC / 18
Carbenoxolone or its salts I DEC / 13
Carbetocin or its salts I DEC / 13
Carbidopa or its salts I DEC / 13
Carbimazole I DEC / 13
Carbinoxamine or its salts III SEP / 98
Carbocisteine I DEC / 13
Carbomycin or its salts or derivatives I DEC / 13

1832 result(s)

Print Friendly

Footnotes

  • C - Drug is listed in the Schedule to Part G of the Food and Drug Regulations under the Controlled Drugs and Substances Act
    N - Drug is listed in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
    NR - Drug has not been reviewed by the NDSAC
    PDL - Drug is listed in the Health Canada Prescription Drug List
    TS - Drug is listed in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
    CR - Drug has been recommended for addition to the Controlled Drugs and Substances Act